The Continuous Innovation Indicators (CII) was developed as part of a Lilly Oncology initiative to encourage public policies and health care decisions that speed the development of new medicines, assure cancer treatments respond to the needs and qualities of individual patients, and improve patient access to the most effective cancer medicines. In 2012, the Patient Access to Cancer care Excellence or PACE Global Council convened to identify potential barriers to innovation in oncology research and specific strategies to remove obstacles to improved cancer care. From this meeting emerged a recognition of the need to build understanding among researchers, policymakers, and patient advocates of the contributions of continuous innovation in the fight against cancer. Watch a White Board Video and Download Brochure
*** A journal article authored by RLA staff and collaborators, Proof-of-concept study: Homomorphically encrypted data can support real-time learning in personalized cancer medicine, was recognized by the International Medical Informatics Association (IMIA) as one of the of the best papers of 2019 in the Clinical Research Informatics arena.
RLA’s initial role was to conduct for the Global Council an analysis of the public policy environment and barriers to rapid research and development in oncology. RLA then developed the Continuous Innovation Indicators (CII) – the first, evidence-based, customizable online tool to review progress against cancer over time. The CII, officially launched in 2015, provides an interactive platform for conducting a variety of analyses across 12 types of cancer. RLA annually updated the CII through 2020 with the latest data and presented consequent research at scientific conferences.
PACE Continuous Innovation Indicators—a novel tool to measure progress in cancer treatments (eCancerMedicalScience, 2015)
Dynamic value assessments in oncology supported by the PACE Continuous Innovation Indicators (Future Oncology, 2017)
The PACE continuous innovation Indicators: A flexible tool to evaluate progress in cancer treatments (Journal of Clinical Oncology, 2017)
Proof-of-concept study: Homomorphically encrypted data can support real-time learning in personalized cancer medicine (BMC Medical Informatics and Decision Making, 2019)
RLA is a participant in the Small Business Administration 8(a) Business Development Program
RLA is recognized by the Small Business Administration as an Economically Disadvantaged Woman-Owned Small Business
© 2021 Rose Li and Associates, Inc.